Advertisement

Medical Oncology

, 33:35 | Cite as

A study of the role of Notch1 and JAG1 gene methylation in development of breast cancer

  • Huapeng Sun
  • Kun Li
  • Shiqiang ShenEmail author
Original Paper

Abstract

This study is to explore the roles of gene methylation of Notch1 and JAG1 in development of invasive ductal carcinoma of breast. Quantitative analysis the DNA methylation levels of Notch1 and JAG1 gene by the MassARRAY method in invasive ductal carcinoma of breast (IDC; n = 89), atypical ductal hyperplasia of breast (ADH; n = 11), and ordinary ductal hyperplasia of breast (UDH; n = 20). The expressions of JAG1 and Notch1 protein in four breast tissues were detected by immunohistochemistry SP method. (1) Positive expression rates of Notch1 protein in IDC and DCIS were 88.7 % (79/89) and 70.0 % (14/20), respectively, which were significantly higher than the levels in ADH (36.0 %, 4/11) and UDH (25.0 %, 5/20; P < 0.05). Notch1 protein expression was significant positively correlated with lymph node metastasis, pathological grades, and TNM stages of IDC. (2) Positive expression rates of JAG1 protein in IDC and DCIS were 89.9 % (80/89) and 75.0 % (15/20), respectively, which were significantly higher than those of ADH (45.0 %, 5/11) and UDH (30.0 %, 6/20; P < 0.05). JAG1 protein expression was significant positive correlation with lymph node metastasis, pathological grades and TNM stages of IDC. There is an overall hypomethylation alteration of Notch1 and JAG gene in IDC, with corresponding over-expression of Notch1 and JAG1 protein. This inverse correlation shows that the alteration of protein expression results from hypomethylation oncogene Notch1 and JAG1, and this change may play an important role in occurrence and progression of breast cancer.

Keywords

Notch1 JAG1 Methylation of DNA Breast cancer Intraductal proliferative lesions of lacteal gland MassARRAY 

Notes

Compliance with ethical standards

Conflicts of interest

We declare that we have no financial or commercial conflicts of interest pertaining to this study.

References

  1. 1.
    Parr C, Watkins G, Jiang WG. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumor clinicopathological parameters in human breast cancer. Int J Mol Med. 2004;14(5):779–86.PubMedGoogle Scholar
  2. 2.
    Hao L, Rizzo P, Osipo C, et al. Notch-1 activates estrogen receptor-alpha-dependent transcription via IK Kalpha in breast cancer cells. Oncogene. 2010;29(2):201–13.CrossRefPubMedGoogle Scholar
  3. 3.
    Mitsuhashi Y, Horiuchi A, Miyamoto T, et al. Prognostic significance of Notch signaling molecules and their involvement in the invasiveness of endometrial carcinoma cells. Histopathology. 2012;60(5):826–37.CrossRefPubMedGoogle Scholar
  4. 4.
    Koch U, Radtke F. Notch signaling in solid tumors. Curr Top Dev Biol. 2010;92:411–55.CrossRefPubMedGoogle Scholar
  5. 5.
    Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148–59.CrossRefPubMedGoogle Scholar
  6. 6.
    Agrawal Anshu, Murphy RF, Agrawal DK. DNA methylation in breast and colorectal cancers. Mod Pathol. 2007;20(7):711–21.CrossRefPubMedGoogle Scholar
  7. 7.
    Itoh H, Lwasaki M, Kasuga Y, et al. Association between serum organochlorines and global methylation level of leukocyte DNA among Japanese women: a cross-sectional study. Sci Total Environ. 2014;490(15):603–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Siegel R, Ma J, Jemal A. Cancer statistics 2014. CA Cancer J Clin. 2014;64(1):9–29.CrossRefPubMedGoogle Scholar
  9. 9.
    Han J, Hendzel MJ, Allalunis TJ. Notch signaling as a therapeutic target for breast cancer treatment? Breast Cancer Res. 2011;13(3):210–6.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Jonusiene V, Sasnauskiene A, Lachei N, et al. Down-regulated expression of Notch signaling molecules in human endometrial cancer. Med Oncol. 2013;30(1):438–45.CrossRefPubMedGoogle Scholar
  11. 11.
    Wael H, Yoshida R, Kudoh S, et al. Notch1 signaling controls cell proliferation, apoptosis and differentiation in lung carcinoma. Lung Cancer. 2014;13(5):210–4.Google Scholar
  12. 12.
    Dominguez M. Oncogenic programmes and Notch activity: an ‘organized crime’? Semin Cell Dev Biol. 2014;28(4):78–85.CrossRefPubMedGoogle Scholar
  13. 13.
    Zardwi SJ, Zardawi I, McNeil CM, et al. High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology. 2010;56(3):286–96.CrossRefGoogle Scholar
  14. 14.
    Reedijk M, Odorcic S, Chang L, et al. High-level coexpression of JAG1 and notch1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005;65:8530–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54(5):716–27.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ellis L, Atadja PW, Johnstone RW. Epigeneties in cancer: targeting chromatin modifications. Mol Cancer Ther. 2009;8(6):1409–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Haller F, Moskalev EA, Faucz FR, et al. Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocr Relat Cancer. 2014;21(4):567–77.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Gautrey HE, van Otterdijk SD, Cordell HJ, et al. DNA methylation abnormalities at gene promoters are extensive and variable in the elderly and phenocopy cancer cells. FASEB J. 2014;28(7):3261–72.CrossRefPubMedGoogle Scholar
  19. 19.
    Avraham Ayelet, Cho Sean Soonweng, Uhlmann Ronit, et al. Tissue specific DNA methylation in normal human breast epithelium and in breast cancer. PLoS One. 2014;9(3):1–8.CrossRefGoogle Scholar
  20. 20.
    Tokaraz P, Blasiak J. Role of DNA methylation in colorectal cancer. Postepy Biochem. 2013;59(3):267–79.Google Scholar
  21. 21.
    Aran D, Sabato S, Hellman A. DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome Biol. 2013;14(3):2–4.CrossRefGoogle Scholar
  22. 22.
    Fukushige S, Horii A. DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers. Tohoku J Exp Med. 2013;229(3):173–85.CrossRefPubMedGoogle Scholar
  23. 23.
    Sharma G, Mirza S, Parshad R, et al. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients[J]. Clin Biochem. 2010;43(4–5):373–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Fujita N, Kagara N, Yamamoto N, et al. Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis. Oncol Lett. 2014;8(1):397–403.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Rao X, Evans J, Chae H, et al. CpG island shore methylation regulates caveolin-1 expression in breast cancer. Oncogene. 2013;32(38):4519–28.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Jiao F, Bai SY, Ma Y, et al. DNA methylation of heparanase promoter influences its expression and associated with the progression of human breast cancer. PLoS One. 2014;9(3):1–12.Google Scholar
  27. 27.
    Heyn H, Sayols S, Moutinho C, et al. Linkage of DNA methylation quantitative trait loci to human cancer risk. Cell Rep. 2014;7(2):331–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of General SurgeryRenmin Hospital of Wuhan UniversityWuhanPeople’s Republic of China
  2. 2.Department of Hepatobiliary and Pancreatic SurgeryZhongnan Hospital of Wuhan UniversityWuhanPeople’s Republic of China

Personalised recommendations